Clinical Trial Update: A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating ASP0113, a therapeutic vaccine, in CMV-seropositive recipients undergoing allogeneic hematopoietic cell transplantation has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• ASP0113

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT) | Phase 3 | Status: COMPLETED | Results posted: 2018-11-28